Immutep Limited (IMMP)

Market Cap	61.62M -75.2%
Revenue (ttm)	5.28M +62.4%
Net Income	-55.97M
EPS	-0.04
Shares Out	1.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	919,378
Open	0.5010
Previous Close	0.4940
Day's Range	0.4910 - 0.5394
52-Week Range	0.2928 - 3.5300
Beta	2.36
Analysts	Hold
Price Target	0.72 (+43.17%)
Earnings Date	Jun 29, 2026

About IMMP

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: IMMP
• Website: https://www.immutep.com

Financial Performance

In fiscal year 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD

Analyst Summary

According to one analyst, the rating for IMMP stock is "Hold" and the 12-month stock price target is $0.72.

Price Target

$0.72

(43.17% upside)

Analyst Consensus: Hold